Regenosca announces completion of First‑in‑Human clinical trial

Lausanne, Switzerland – December 1, 2025 Regenosca is proud to announce the successful completion of its First‑in‑Human (FIH) clinical trial, marking a major milestone in the development of its TissueSpan™ regenerative implant platform.

This achievement represents an important step in translating Regenosca’s regenerative technology from preclinical research into clinical practice. The First‑in‑Human study was designed to evaluate the feasibility and safety of TissueSpan™ in a clinical setting, providing critical insights to guide the next phases of development in reconstructive urology.

Completing the FIH trial reflects the dedication and close collaboration between clinicians, researchers, and the Regenosca team, and underscores the company’s commitment to advancing natural, bioabsorbable solutions for soft‑tissue repair that aim to restore function while avoiding donor‑site morbidity.

Regenosca would like to express its sincere gratitude to the patients, investigators, clinical partners, and collaborators who made this milestone possible through their trust, expertise, and engagement.

Building on this important achievement, Regenosca now looks ahead to the next stages of clinical and industrial development, continuing its mission to improve outcomes for patients through regenerative surgical innovation.